
Incyte (INCY) Stock Forecast & Price Target
Incyte (INCY) Analyst Ratings
Bulls say
Incyte demonstrated a strong performance in the fourth quarter, driven primarily by robust demand for its leading drug, Jakafi, which generated $773 million in revenue, surpassing expectations and reflecting minimal impact from competition. The company also reported promising clinical results for its dermatology product, Opzelura, indicating significant improvements for patients with atopic dermatitis, further enhancing its revenue potential. Additionally, the positive commercial trajectory of Incyte's legacy products, alongside a promising pipeline featuring best-in-class assets like povorcitinib, suggests a sustained growth outlook, particularly as the company navigates the upcoming Jakafi patent cliff in 2028.
Bears say
Incyte's negative outlook is influenced by eroding pricing power for its lead drug, Jakafi, alongside anticipated slowing usage. The company faces significant risks, including performance issues with its earlier-stage pipeline, competitive pressures, and various regulatory uncertainties that could hinder Jakafi's lifecycle. Additionally, a lack of compelling clinical data for its products and emerging competitors may adversely affect future sales growth and overall financial performance.
This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.
Incyte (INCY) Analyst Forecast & Price Prediction
Start investing in Incyte (INCY)
Order type
Buy in
Order amount
Est. shares
0 shares